Skip to content
All resources

SS-31

SS-31 (Elamipretide) Eye Research: What the Macular Degeneration and LHON Trials Found

JH

By

· 11 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 7 sections
  1. What SS-31 is, and why the retina is the obvious place to test it
  2. What did the animal vision studies show?
  3. The ReCLAIM trials in dry macular degeneration
  4. Leber hereditary optic neuropathy
  5. Is elamipretide FDA approved, and is it approved for the eyes?
  6. What is SS-31's status in Canada?
  7. Frequently asked questions

SS-31 (elamipretide) has a real but mixed record in eye research. Mouse studies reported preserved visual function. Two small open-label phase 1 trials in dry age-related macular degeneration (AMD) reported gains in low-light acuity. But the randomized phase 2 trial, ReCLAIM-2, missed both its primary endpoints, and a 12-patient trial in Leber hereditary optic neuropathy (LHON) missed its main endpoint as well. A phase 3 AMD trial is running. No regulator has approved elamipretide for any eye disease.

An anatomical eye model cut away to show the retina, with a fundus image on a monitor behind
Illustration: the retina, where mitochondrial eye research looks.

What SS-31 is, and why the retina is the obvious place to test it

SS-31 is a synthetic tetrapeptide. Its four residues include an unnatural dimethyltyrosine, and it is described in the literature as mitochondria-targeted: it reaches the inner mitochondrial membrane rather than acting at the cell surface. The developer's name for it is elamipretide, and some early papers call it MTP-131. Its proposed target is a lipid, not a receptor. Birk and colleagues used a fluorescent analogue to show that SS-31 binds cardiolipin with high affinity. Cardiolipin is the phospholipid that holds the folded cristae of the inner membrane together and anchors the electron-transport complexes. In that rat kidney ischemia work, the SS-31–cardiolipin complex also inhibited cytochrome c's peroxidase activity, which otherwise oxidises cardiolipin during injury (PMID 23813215).

That makes it a different kind of molecule from a general antioxidant like glutathione, and different from a signalling peptide like MOTS-c. The claim is structural: keep the membrane that the respiratory chain sits in intact, and electron transport stays efficient.

The retina makes a natural test case. Photoreceptors and the retinal pigment epithelium are among the most energy-hungry tissues in the body. Mitochondrial dysfunction shows up early in dry AMD. LHON is caused outright by mutations in mitochondrial DNA. A drug aimed at mitochondrial membranes either shows up in the eye or it probably shows up nowhere.

What did the animal vision studies show?

Two mouse studies from the same group carry most of the preclinical eye story. Both are worth reading for their limits as much as their findings.

In mouse models of diabetes, Alam and colleagues measured spatial vision behaviourally with an optokinetic test. They reported that visual decline began before overt metabolic abnormalities, and that MTP-131 reversed it without improving blood glucose or body weight (PMID 26035391). That last detail is the interesting one. It suggests the effect, if real, ran through retinal or neural tissue rather than through better glycaemic control.

In ageing mice, the same group found photopic acuity fell to roughly 40% below normal by 34 months. Elamipretide started at 18 months slowed the decline, and started at 24 months it brought acuity back to normal within two months. Recovered function persisted for at least three months after treatment stopped. Two different delivery methods gave comparable effects, and night (scotopic) vision was largely unaffected by age or treatment (PMID 34766182).

Two cautions. First, the read-out in both papers is behavioural: a head-tracking response to moving gratings, not retinal imaging or electrophysiology. Second, the disclosures matter. Two authors are principals of the company that makes the vision-testing equipment, and the 2015 paper notes that a co-author and his institution had financial interests in the company developing the peptide. None of that makes the data wrong. It does mean independent replication carries more weight than usual, and a mouse optokinetic response is a long way from a human reading an eye chart in dim light.

The ReCLAIM trials in dry macular degeneration

StudyDesignPatientsPrimary endpointWhat happened
ReCLAIM, noncentral GA cohort (phase 1)Open-label, single centre, 24 weeks, no control19 enrolled, 15 completedSafety and tolerabilityTolerated, no serious adverse events; exploratory mean gain of about 5 letters in low-luminance acuity
ReCLAIM, high-risk drusen cohort (phase 1)Open-label, single centre, 24 weeks, no control21 enrolled, 18 completedSafety and tolerabilityTolerated; exploratory gains in low-luminance acuity and reading; no change in drusen volume, autofluorescence, microperimetry or dark adaptation
ReCLAIM-2 (phase 2)Randomized 2:1, placebo-controlled, double-masked, 48 weeks176Low-luminance acuity and geographic atrophy growthBoth primary endpoints missed; nominal slowing of ellipsoid-zone loss
ReNEW (phase 3)Registered, active, not recruiting313 enrolledRate of photoreceptor loss at week 48No results posted

The phase 1 studies were designed to test feasibility. Their visual results are labelled exploratory, and they should be read that way (PMID 36246181; PMID 36246187). With no control arm, a few letters of improvement on repeated acuity testing can come from patients learning the test, from regression to the mean, or from expectation, as easily as from the drug. In the drusen cohort, every structural measure stayed flat while the functional ones moved. That is the pattern you would expect if part of the signal was test familiarity.

ReCLAIM-2 was the real test. It randomized 176 people aged 55 or over with geographic atrophy, 117 to elamipretide and 59 to placebo, for 48 weeks (NCT03891875 on ClinicalTrials.gov). Neither primary endpoint reached statistical significance: change in low-luminance best-corrected acuity, or growth of the atrophic area on OCT. The paper leads with secondary findings. Progression of complete ellipsoid-zone loss was 43% lower than placebo, partial ellipsoid-zone degradation progressed 47% less, and more patients gained 10 or more letters in low light (14.6% vs 2.1%). All three carry nominal p-values, meaning they were not adjusted for having missed the primary analysis (PMID 39605874). Adverse events were reported in 86% of the elamipretide group and 71% of the placebo group, most often reactions at the administration site.

The ellipsoid zone is the band on OCT that corresponds to photoreceptor inner segments, and its loss precedes visible atrophy. It is a reasonable thing to measure. But it became the headline only after the planned endpoints failed. The authors report that ellipsoid-zone loss is the regulator-agreed primary endpoint for phase 3, and the phase 3 registry entry matches: ReNEW lists the rate of change in the macular area of photoreceptor loss at week 48 as its primary outcome (NCT06373731). That is the correct sequence: a secondary signal becomes a pre-declared primary endpoint in a larger trial, which then confirms it or doesn't. Until ReNEW reports, the honest summary is that elamipretide has not been shown to slow dry AMD. For why missed primaries and nominal secondaries are read this way, see how to read a peptide study.

Leber hereditary optic neuropathy

LHON is a maternally inherited mitochondrial disease that destroys retinal ganglion cells, usually in young men, and it is about as direct a test of a mitochondrial drug as the eye offers. Karanjia and Sadun ran a single-centre phase 2 trial in 12 patients carrying the m.11778G>A mutation, using an ophthalmic formulation. Treated eyes were compared against vehicle-treated fellow eyes for 52 weeks under double masking, followed by an open-label extension (PMID 37923251).

The primary efficacy endpoint was change in best-corrected visual acuity, and the treated eyes did not differ from vehicle eyes at any time point. A post hoc analysis found a larger change in central visual-field mean deviation in treated eyes. Colour discrimination and contrast sensitivity improved during the open-label extension, but both groups improved, with no comparator. The treatment was well tolerated with no serious adverse events. The authors call the findings encouraging but in need of further exploration. With 12 patients, a missed primary endpoint, a post hoc positive and an uncontrolled extension, that is the most the data can carry.

Is elamipretide FDA approved, and is it approved for the eyes?

It is approved, but not for the eyes. In September 2025 the US Food and Drug Administration granted accelerated approval to elamipretide (brand name Forzinity) to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg (PMID 41335372). Barth syndrome is an ultra-rare X-linked disorder in which a defective tafazzin enzyme leaves cardiolipin abnormally formed. A cardiolipin-binding drug is a mechanistically tidy fit for it.

The road there was not straightforward. In the randomized crossover part of the TAZPOWER trial (12 patients), neither primary endpoint was met: the six-minute walk test or a Barth symptom score. The improvements came in the open-label extension (PMID 33077895), which ran to 168 weeks with eight patients reaching the final visit (PMID 38602181). Accelerated approval in the US is granted on evidence considered reasonably likely to predict benefit, and further confirmation is generally required.

None of this is an ophthalmic indication. The same review notes that elamipretide is in phase 3 development for dry AMD and for mitochondrial myopathies, which is to say not yet approved for either.

What is SS-31's status in Canada?

We are not aware of any Health Canada market authorization for elamipretide, for Barth syndrome or anything else, and the "First Approval" profile in Drugs describes the US decision as its first anywhere. Researchers can check current status in Health Canada's Drug Product Database. Material sold for laboratory research is not a licensed drug, and an approval of a regulated product in another country does not attach to it. The Canadian framework is set out in peptides and Canadian law.

Where this leaves the eye question: mechanistically coherent, positive in mice, positive in uncontrolled human cohorts, negative on the primary endpoints of both controlled human eye trials published so far, and awaiting a phase 3 result on a structural endpoint. For a broader view of mitochondrial targets, see NAD+ and the mitochondrion. Nothing here is medical, dosing, or therapeutic guidance.

Supplied here for laboratory use: SS-31. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

Frequently asked questions

Does SS-31 restore vision in people? No controlled trial has shown that. Both randomized human eye trials published so far missed their primary visual endpoints: ReCLAIM-2 in dry AMD and the LHON study. The acuity gains came from uncontrolled phase 1 cohorts, open-label extensions and post hoc or nominal analyses, which can suggest an effect but cannot establish one.

What is the ellipsoid zone, and why does the AMD research focus on it? It is a band seen on OCT retinal scans that corresponds to the photoreceptor inner segments. Its loss comes before visible atrophy and before measurable vision loss. In ReCLAIM-2 it was a secondary measure showing nominal slowing, and it is now the primary endpoint of the phase 3 ReNEW trial, which has not reported.

Is elamipretide the same as SS-31 and MTP-131? Yes. SS-31 is the original laboratory name from the Szeto group, MTP-131 appears in some earlier papers, and elamipretide is the international nonproprietary name used in clinical trials. Forzinity is the brand name of the US-approved drug product. A research vial labelled SS-31 is not that regulated product.

Why would a Barth syndrome drug be studied in eye disease? Both lines of research rest on the same mechanism. Elamipretide binds cardiolipin in the inner mitochondrial membrane, Barth syndrome is a disorder of cardiolipin, and the retina has very high mitochondrial energy demand. The shared rationale does not transfer an approval: each indication needs its own trials.

Has SS-31 been tested for glaucoma or diabetic retinopathy in humans? Not in any controlled human trial we could find. Glaucoma and diabetic-retinopathy work on SS-31 is cell and animal research, including the diabetic-mouse vision study described above. The human ophthalmic trials have been in dry age-related macular degeneration and Leber hereditary optic neuropathy.

Selected Research References

  1. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261. pubmed.ncbi.nlm.nih.gov/23813215
  2. Alam NM, Mills WC, Wong AA, et al. A mitochondrial therapeutic reverses visual decline in mouse models of diabetes. Dis Model Mech. 2015;8(7):701-710. pubmed.ncbi.nlm.nih.gov/26035391
  3. Alam NM, Douglas RM, Prusky GT. Treatment of age-related visual impairment with a peptide acting on mitochondria. Dis Model Mech. 2022;15(3):dmm048256. pubmed.ncbi.nlm.nih.gov/34766182
  4. Mettu PS, Allingham MJ, Cousins SW. Phase 1 clinical trial of elamipretide in dry age-related macular degeneration and noncentral geographic atrophy: ReCLAIM NCGA study. Ophthalmol Sci. 2022;2(1):100086. pubmed.ncbi.nlm.nih.gov/36246181
  5. Allingham MJ, Mettu PS, Cousins SW. Phase 1 clinical trial of elamipretide in intermediate age-related macular degeneration and high-risk drusen: ReCLAIM high-risk drusen study. Ophthalmol Sci. 2022;2(1):100095. pubmed.ncbi.nlm.nih.gov/36246187
  6. Ehlers JP, Hu A, Boyer D, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2025;5(1):100628. pubmed.ncbi.nlm.nih.gov/39605874
  7. Karanjia R, Sadun AA. Elamipretide topical ophthalmic solution for the treatment of subjects with Leber hereditary optic neuropathy: a randomized trial. Ophthalmology. 2024;131(4):422-433. pubmed.ncbi.nlm.nih.gov/37923251
  8. Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471-478. pubmed.ncbi.nlm.nih.gov/33077895
  9. Thompson WR, Manuel R, Abbruscato A, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138. pubmed.ncbi.nlm.nih.gov/38602181
  10. Shirley M. Elamipretide: first approval. Drugs. 2026;86(3):377-383. pubmed.ncbi.nlm.nih.gov/41335372

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.